ID: ALA4464640

Max Phase: Preclinical

Molecular Formula: C32H41N3O6

Molecular Weight: 563.70

Molecule Type: Unknown

Representations

Canonical SMILES:  COc1ccc(C[C@H](NC(=O)[C@@H](C)NC(=O)C2CCCCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1

Standard InChI:  InChI=1S/C32H41N3O6/c1-21(33-30(38)24-12-8-5-9-13-24)29(37)35-27(19-23-14-16-25(40-3)17-15-23)31(39)34-26(28(36)32(2)20-41-32)18-22-10-6-4-7-11-22/h4,6-7,10-11,14-17,21,24,26-27H,5,8-9,12-13,18-20H2,1-3H3,(H,33,38)(H,34,39)(H,35,37)/t21-,26+,27+,32-/m1/s1

Standard InChI Key:  JXHAWXRODIYNNP-LCFAYYECSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 563.70

Molecular Weight (Monoisotopic): 563.2995

AlogP: 2.89

#Rotatable Bonds: 13

Polar Surface Area: 126.13

Molecular Species: NEUTRAL

HBA: 6

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.96

CX Basic pKa:

CX LogP: 4.06

CX LogD: 4.06

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.32

Np Likeness Score: -0.11

References

1. Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, Moebius DC, Kirk C, McMinn DL..  (2018)  Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).,  61  (24): [PMID:30380863] [10.1021/acs.jmedchem.8b01201]

Source

Source(1):

• Scientific Literature